Volume 90 Issue 32 | p. 11 | News of The Week
Issue Date: August 6, 2012

Challenging Generic Drug Deals

Pharma companies in Europe, U.S. face scrutiny over so-called pay-to-delay tactics.
Department: Business
Keywords: patent settlement, generic pharmaceuticals

The European Commission last week claimed that patent settlements between the French drug company Servier and several of its generics competitors may be delaying entry of a generic version of the heart drug perindopril in Europe. The accusation is the latest by officials on both sides of the Atlantic involving the so-called pay-for-delay tactic of drug firms to thwart generic drug competition.

The EC lists generic drug manufacturers Teva . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society